The Decoder 🧠 Models 👁 9 ⏱ 1 min read

OpenAI acquires Orchestra Bio to build AI agents that speed up drug development

OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on…

Annons
Annons
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research. The article OpenAI acquires Orchestra Bio to build AI agents that speed up drug development appeared first on The Decoder.

Source: The Decoder — Published — Category: Models

🔗 Read full article on The Decoder →
🏷️ Topics: OpenAI

More from The Decoder today

Adobe is testing how well AI agents can use editing tools like a Photoshop professional would 21h ago Empathetic prompts can turn AI chatbots into seemingly traumatized conversational partners 21h ago

More in Models

The Decoder21h ago

Adobe is testing how well AI agents can use editing tools like a Photoshop professional would
The Decoder21h ago

Empathetic prompts can turn AI chatbots into seemingly traumatized conversational partners
The Decoder23h ago

Chinese AI models are politically complex, not just government mouthpieces, study finds
The Decoder24h ago

OpenAI is steering ChatGPT users toward more paid usage
The Decoder1d ago

Google wants video AI to understand what people need as they work
The Decoder1d ago

OpenAI's upcoming chat-and-work merger in ChatGPT signals the end of all-you-can-prompt pricing
Annons
Annons